The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
CACA 2025 | New treatment strategies and biomarker advances for esophageal cancer
Hongjing Jiang, MD, Tianjin Medical University Cancer Hospital, Tianjin, China, gives an overview of challenges in managing esophageal cancer in China, which has one of the highest rates of esophageal cancer in the world. Advances in neoadjuvant chemoimmunotherapy has enabled reduced chemotherapy doses, and novel biomarkers such as TRGC2+ NKT cells will complement current detection techniques. This interview took place at the 2025 Chinese Anti-Cancer Association (CACA) Science & Technology Award Talks in Kunming, China.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
